View in EDS

Reply to R.L. Nussbaum et al and J.S. Dolinsky et al.

Saved in:
Bibliographic Details
Title: Reply to R.L. Nussbaum et al and J.S. Dolinsky et al.
Authors: Balmaña J; Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA., Nathanson K; Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA., Offit K; Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA., Robson M; Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA., Domchek S; Judith Balmaña, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Katherine Nathanson, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA; Kenneth Offit and Mark Robson, Memorial Sloan Kettering Cancer Center, New York, NY; and Susan Domchek, Perelman School of Medicine at the University of Pennsylvania and Basser Center for BRCA, Philadelphia, PA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2017 Apr 10; Vol. 35 (11), pp. 1262-1263. Date of Electronic Publication: 2017 Jan 30.
Publication Type: Letter; Research Support, Non-U.S. Gov't; Comment
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.2016.71.3859